Avalo Therapeutics
AVTX
22 hedge funds and large institutions have $863K invested in Avalo Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.21% less ownership
Funds ownership: 0.29% → 0.08% (-0.21%)
15% less funds holding
Funds holding: 26 → 22 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
95% less capital invested
Capital invested by funds: $16M → $863K (-$15.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$701K |
| 2 |
VF
Virtu Financial
New York
|
+$91.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$82.8K |
| 4 |
BlackRock
New York
|
+$59.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$57.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$7.73M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.93M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$831K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$708K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$700K |
AVTX Hedge Fund Activity: Q2 2023 in Review
22 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2023, worth a combined $863K — down 95% from $16M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AVTX and 5 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was VR Adviser, adding an estimated $701K. The largest seller was Armistice Capital, exiting entirely with an estimated $7.73M sold.
- 22 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2023, down from 26 in Q1 2023.
- Funds reported $863K of Avalo Therapeutics stock for Q2 2023, down 95% quarter-over-quarter.
- 5 funds opened new Avalo Therapeutics positions in Q2 2023 and 9 closed out, a net change of -4 holders.
- The largest Avalo Therapeutics buyer in Q2 2023 was VR Adviser, an estimated $701K added.
- The largest Avalo Therapeutics seller in Q2 2023 was Armistice Capital, an estimated $7.73M sold.
Based on aggregated 13F filings for Q2 2023.